Sign inJoin waitlistJoin the waitlist

Mary Scholand

Professor · Univ of Utah Sch of Med

Credentials: · · · ·

History

Univ of Utah Sch of Med
Present

University of Utah School of Medicine
2021–2023
Pediatrics
Univ of Utah Sch of Med
2018–2021
Internal Medicine
Barnes-Jewish Hospital
1990–1993
Washington University School of Medicine
1986–1990
Northwestern University
1982–1986

Research

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial
The Lancet Respiratory Medicine · 2016 · 831 citations
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial
The Lancet Respiratory Medicine · 2020 · 243 citations
A candidate gene approach identifies the CHRNA5-A3-B4 region as a risk factor for age-dependent nicotine addiction
PLoS Genetics · 2008 · 216 citations

Tracy Frech
15 papers · 1 as a resident
Kevin Flaherty
11 papers
RB
Robert Baughman
11 papers
LS
Lesley Saketkoo
10 papers
SN
Steven Nathan
9 papers
Ayodeji Adegunsoye
8 papers
Evans Perez
8 papers
Ganesh Raghu
8 papers
John Hoidal
8 papers
Oksana Shlobin
8 papers
David Lynch
7 papers
Elana Bernstein
7 papers

Clinical trials

Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Principal investigator · Completed · Phase 2
Kyntra Bio
2013–2017
AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis
Principal investigator · Terminated · Phase 3
Duke University
2009–2011
Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF
Principal investigator · Completed · Phase 3
Duke University
2009–2014
Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis
Site PI · Not yet recruiting · Phase 2
University of Alabama at Birmingham
2026–2031